Your browser doesn't support javascript.
loading
A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group).
Wu, Zhenjie; Chen, Qi; Djaladat, Hooman; Minervini, Andrea; Uzzo, Robert G; Sundaram, Chandru P; Rha, Koon H; Gonzalgo, Mark L; Mehrazin, Reza; Mazzone, Elio; Marcus, Jamil; Danno, Alyssa; Porter, James; Asghar, Aeen; Ghali, Fady; Guruli, Georgi; Douglawi, Antoin; Cacciamani, Giovanni; Ghoreifi, Alireza; Simone, Giuseppe; Margulis, Vitaly; Ferro, Matteo; Tellini, Riccardo; Mari, Andrea; Srivastava, Abhishek; Steward, James; Al-Qathani, Ali; Al-Mujalhem, Ahmad; Bhattu, Amit Satish; Mottrie, Alexander; Abdollah, Firas; Eun, Daniel D; Derweesh, Ithaar; Veccia, Alessandro; Autorino, Riccardo; Wang, Linhui.
Afiliación
  • Wu Z; Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Chen Q; Department of Health Statistics, Naval Medical University, Shanghai, China.
  • Djaladat H; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Minervini A; Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
  • Uzzo RG; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Sundaram CP; Indiana University School of Medicine, Indianapolis, IN, USA.
  • Rha KH; Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Gonzalgo ML; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Mehrazin R; Icahn School of Medicine at Mount Sinai, Department of Urology, New York, NY, USA.
  • Mazzone E; OLV Hospital, Aalst, Belgium;ORSI Academy, Melle, Belgium.
  • Marcus J; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
  • Danno A; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
  • Porter J; Swedish Medical Center, Seattle, WA, USA.
  • Asghar A; Department of Urology, Temple University, Philadelphia, PA, USA.
  • Ghali F; Department of Urology, UCSD, San Diego, CA, USA.
  • Guruli G; Division of Urology, VCU Health, Richmond, VA, USA.
  • Douglawi A; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Cacciamani G; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Ghoreifi A; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Simone G; Department of Urology, Regina Elena National Cancer Institute, Rome, Italy.
  • Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Ferro M; Division of Urology - European Institute of Oncology, IRCCS.
  • Tellini R; Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
  • Mari A; Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
  • Srivastava A; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Steward J; Indiana University School of Medicine, Indianapolis, IN, USA.
  • Al-Qathani A; Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Al-Mujalhem A; Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Bhattu AS; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Mottrie A; OLV Hospital, Aalst, Belgium;ORSI Academy, Melle, Belgium.
  • Abdollah F; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
  • Eun DD; Department of Urology, Temple University, Philadelphia, PA, USA.
  • Derweesh I; Department of Urology, UCSD, San Diego, CA, USA.
  • Veccia A; Division of Urology, VCU Health, Richmond, VA, USA.
  • Autorino R; Division of Urology, VCU Health, Richmond, VA, USA.
  • Wang L; Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, China. Electronic address: wanglinhui@smmu.edu.cn.
Eur Urol Focus ; 8(1): 173-181, 2022 Jan.
Article en En | MEDLINE | ID: mdl-33549537
ABSTRACT

BACKGROUND:

Postoperative renal function impairment represents a main limitation for delivering adjuvant chemotherapy after radical nephroureterectomy (RNU).

OBJECTIVE:

To create a model predicting renal function decline after minimally invasive RNU. DESIGN, SETTING, AND

PARTICIPANTS:

A total of 490 patients with nonmetastatic UTUC who underwent minimally invasive RNU were identified from a collaborative database including 17 institutions worldwide (February 2006 to March 2020). Renal function insufficiency for cisplatin-based regimen was defined as estimated glomerular filtration rate (eGFR) <50 ml/min/1.73 m2 at 3 mo after RNU. Patients with baseline eGFR >50 ml/min/1.73 m2 (n = 361) were geographically divided into a training set (n = 226) and an independent external validation set (n = 135) for further analysis. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

Using transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines, a nomogram to predict postoperative eGFR <50 ml/min/1.73 m2 was built based on the coefficients of the least absolute shrinkage and selection operation (LASSO) logistic regression. The discrimination, calibration, and clinical use of the nomogram were investigated. RESULTS AND

LIMITATIONS:

The model that incorporated age, body mass index, preoperative eGFR, and hydroureteronephrosis was developed with an area under the curve of 0.771, which was confirmed to be 0.773 in the external validation set. The calibration curve demonstrated good agreement. Besides, the model was converted into a risk score with a cutoff value of 0.583, and the difference between the low- and high-risk groups both in overall death risk (hazard ratio [HR] 4.59, p < 0.001) and cancer-specific death risk (HR 5.19, p < 0.001) was statistically significant. The limitation mainly lies in its retrospective design.

CONCLUSIONS:

A nomogram incorporating immediately available clinical variables can accurately predict renal insufficiency for cisplatin-based adjuvant chemotherapy after minimally invasive RNU and may serve as a tool facilitating patient selection. PATIENT

SUMMARY:

We have developed a model for the prediction of renal function loss after radical nephroureterectomy to facilitate patient selection for perioperative chemotherapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_kidney_renal_pelvis_ureter_cancer Asunto principal: Cisplatino / Nefroureterectomía Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Urol Focus Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_kidney_renal_pelvis_ureter_cancer Asunto principal: Cisplatino / Nefroureterectomía Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Urol Focus Año: 2022 Tipo del documento: Article País de afiliación: China
...